Which has better valuation & earnings, HQL or NUV?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio abrdn Life Sciences Investors N/A N/A N/A N/A N/A Nuveen Municipal Value Fund N/A N/A N/A N/A N/A

Is HQL or NUV more profitable?

Company Net Margins Return on Equity Return on Assets abrdn Life Sciences Investors N/A N/A N/A Nuveen Municipal Value Fund N/A N/A N/A

Which has stronger earnings & valuation, GAB or HQL?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gabelli Equity Trust N/A N/A N/A N/A N/A abrdn Life Sciences Investors N/A N/A N/A N/A N/A

Is GAB or HQL more profitable?

Company Net Margins Return on Equity Return on Assets Gabelli Equity Trust N/A N/A N/A abrdn Life Sciences Investors N/A N/A N/A

Which has stronger earnings & valuation, USA or HQL?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liberty All-Star Equity Fund N/A N/A N/A N/A N/A abrdn Life Sciences Investors N/A N/A N/A N/A N/A

Is USA or HQL more profitable?

Company Net Margins Return on Equity Return on Assets Liberty All-Star Equity Fund N/A N/A N/A abrdn Life Sciences Investors N/A N/A N/A

Which has better valuation and earnings, STEW or HQL?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SRH Total Return Fund N/A N/A N/A N/A N/A abrdn Life Sciences Investors N/A N/A N/A N/A N/A

Is STEW or HQL more profitable?

Company Net Margins Return on Equity Return on Assets SRH Total Return Fund N/A N/A N/A abrdn Life Sciences Investors N/A N/A N/A

Which has stronger valuation & earnings, BCAT or HQL?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BlackRock Capital Allocation Term Trust $223.60M 7.37 N/A N/A N/A abrdn Life Sciences Investors N/A N/A N/A N/A N/A

Is BCAT or HQL more profitable?

Company Net Margins Return on Equity Return on Assets BlackRock Capital Allocation Term Trust N/A N/A N/A abrdn Life Sciences Investors N/A N/A N/A

abrdn Life Sciences Investors (HQL) Competitors

$16.92 -0.26 (-1.51%)

Closing price 06/3/2026 03:58 PM Eastern

Extended Trading

$16.92 +0.00 (+0.03%)

As of 06/3/2026 04:10 PM Eastern

Compare

HQL vs. NUV, GAB, USA, STEW, and BCAT

Should you buy abrdn Life Sciences Investors stock or one of its competitors? MarketBeat compares abrdn Life Sciences Investors with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with abrdn Life Sciences Investors include Nuveen Municipal Value Fund (NUV), Gabelli Equity Trust (GAB), Liberty All-Star Equity Fund (USA), SRH Total Return Fund (STEW), and BlackRock Capital Allocation Term Trust (BCAT). These companies are all part of the "financial services" industry.

How does abrdn Life Sciences Investors compare to Nuveen Municipal Value Fund?

abrdn Life Sciences Investors (NYSE:HQL) and Nuveen Municipal Value Fund (NYSE:NUV) are both small-cap finance companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

32.2% of abrdn Life Sciences Investors shares are owned by institutional investors. Comparatively, 22.5% of Nuveen Municipal Value Fund shares are owned by institutional investors. 10.1% of abrdn Life Sciences Investors shares are owned by company insiders. Comparatively, 1.0% of Nuveen Municipal Value Fund shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
abrdn Life Sciences Investors	N/A	N/A	N/A
Nuveen Municipal Value Fund	N/A	N/A	N/A

abrdn Life Sciences Investors pays an annual dividend of $2.04 per share and has a dividend yield of 12.1%. Nuveen Municipal Value Fund pays an annual dividend of $0.23 per share and has a dividend yield of 2.5%.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
abrdn Life Sciences Investors	N/A	N/A	N/A	N/A	N/A
Nuveen Municipal Value Fund	N/A	N/A	N/A	N/A	N/A

abrdn Life Sciences Investors has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market. Comparatively, Nuveen Municipal Value Fund has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market.

In the previous week, Nuveen Municipal Value Fund had 1 more articles in the media than abrdn Life Sciences Investors. MarketBeat recorded 1 mentions for Nuveen Municipal Value Fund and 0 mentions for abrdn Life Sciences Investors. Nuveen Municipal Value Fund's average media sentiment score of 1.00 beat abrdn Life Sciences Investors' score of 0.00 indicating that Nuveen Municipal Value Fund is being referred to more favorably in the news media.

Company	Overall Sentiment
abrdn Life Sciences Investors	Neutral
Nuveen Municipal Value Fund	Positive

Summary

abrdn Life Sciences Investors beats Nuveen Municipal Value Fund on 4 of the 6 factors compared between the two stocks.

How does abrdn Life Sciences Investors compare to Gabelli Equity Trust?

Gabelli Equity Trust (NYSE:GAB) and abrdn Life Sciences Investors (NYSE:HQL) are both small-cap finance companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Company	Net Margins	Return on Equity	Return on Assets
Gabelli Equity Trust	N/A	N/A	N/A
abrdn Life Sciences Investors	N/A	N/A	N/A

7.2% of Gabelli Equity Trust shares are owned by institutional investors. Comparatively, 32.2% of abrdn Life Sciences Investors shares are owned by institutional investors. 0.8% of Gabelli Equity Trust shares are owned by company insiders. Comparatively, 10.1% of abrdn Life Sciences Investors shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gabelli Equity Trust	N/A	N/A	N/A	N/A	N/A
abrdn Life Sciences Investors	N/A	N/A	N/A	N/A	N/A

In the previous week, Gabelli Equity Trust's average media sentiment score of 1.00 beat abrdn Life Sciences Investors' score of 0.00 indicating that Gabelli Equity Trust is being referred to more favorably in the media.

Company	Overall Sentiment
Gabelli Equity Trust	Positive
abrdn Life Sciences Investors	Neutral

Gabelli Equity Trust has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market. Comparatively, abrdn Life Sciences Investors has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market.

Gabelli Equity Trust pays an annual dividend of $0.60 per share and has a dividend yield of 10.7%. abrdn Life Sciences Investors pays an annual dividend of $2.04 per share and has a dividend yield of 12.1%.

Summary

abrdn Life Sciences Investors beats Gabelli Equity Trust on 4 of the 5 factors compared between the two stocks.

How does abrdn Life Sciences Investors compare to Liberty All-Star Equity Fund?

Liberty All-Star Equity Fund (NYSE:USA) and abrdn Life Sciences Investors (NYSE:HQL) are both small-cap finance companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

In the previous week, Liberty All-Star Equity Fund had 2 more articles in the media than abrdn Life Sciences Investors. MarketBeat recorded 2 mentions for Liberty All-Star Equity Fund and 0 mentions for abrdn Life Sciences Investors. Liberty All-Star Equity Fund's average media sentiment score of 1.19 beat abrdn Life Sciences Investors' score of 0.00 indicating that Liberty All-Star Equity Fund is being referred to more favorably in the media.

Company	Overall Sentiment
Liberty All-Star Equity Fund	Positive
abrdn Life Sciences Investors	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Liberty All-Star Equity Fund	N/A	N/A	N/A
abrdn Life Sciences Investors	N/A	N/A	N/A

Liberty All-Star Equity Fund pays an annual dividend of $0.68 per share and has a dividend yield of 11.7%. abrdn Life Sciences Investors pays an annual dividend of $2.04 per share and has a dividend yield of 12.1%.

Liberty All-Star Equity Fund has a beta of 1.02, meaning that its share price is 2% more volatile than the broader market. Comparatively, abrdn Life Sciences Investors has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liberty All-Star Equity Fund	N/A	N/A	N/A	N/A	N/A
abrdn Life Sciences Investors	N/A	N/A	N/A	N/A	N/A

10.0% of Liberty All-Star Equity Fund shares are owned by institutional investors. Comparatively, 32.2% of abrdn Life Sciences Investors shares are owned by institutional investors. 0.1% of Liberty All-Star Equity Fund shares are owned by insiders. Comparatively, 10.1% of abrdn Life Sciences Investors shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Liberty All-Star Equity Fund and abrdn Life Sciences Investors tied by winning 3 of the 6 factors compared between the two stocks.

How does abrdn Life Sciences Investors compare to SRH Total Return Fund?

SRH Total Return Fund (NYSE:STEW) and abrdn Life Sciences Investors (NYSE:HQL) are both small-cap finance companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

15.6% of SRH Total Return Fund shares are held by institutional investors. Comparatively, 32.2% of abrdn Life Sciences Investors shares are held by institutional investors. 0.1% of SRH Total Return Fund shares are held by insiders. Comparatively, 10.1% of abrdn Life Sciences Investors shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

SRH Total Return Fund has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, abrdn Life Sciences Investors has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market.

SRH Total Return Fund pays an annual dividend of $0.73 per share and has a dividend yield of 4.2%. abrdn Life Sciences Investors pays an annual dividend of $2.04 per share and has a dividend yield of 12.1%.

In the previous week, abrdn Life Sciences Investors' average media sentiment score of 0.00 beat SRH Total Return Fund's score of -1.00 indicating that abrdn Life Sciences Investors is being referred to more favorably in the news media.

Company	Overall Sentiment
SRH Total Return Fund	Negative
abrdn Life Sciences Investors	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SRH Total Return Fund	N/A	N/A	N/A	N/A	N/A
abrdn Life Sciences Investors	N/A	N/A	N/A	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
SRH Total Return Fund	N/A	N/A	N/A
abrdn Life Sciences Investors	N/A	N/A	N/A

Summary

abrdn Life Sciences Investors beats SRH Total Return Fund on 4 of the 5 factors compared between the two stocks.

How does abrdn Life Sciences Investors compare to BlackRock Capital Allocation Term Trust?

BlackRock Capital Allocation Term Trust (NYSE:BCAT) and abrdn Life Sciences Investors (NYSE:HQL) are both small-cap financial services companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BlackRock Capital Allocation Term Trust	$223.60M	7.37	N/A	N/A	N/A
abrdn Life Sciences Investors	N/A	N/A	N/A	N/A	N/A

BlackRock Capital Allocation Term Trust pays an annual dividend of $3.16 per share and has a dividend yield of 20.1%. abrdn Life Sciences Investors pays an annual dividend of $2.04 per share and has a dividend yield of 12.1%.

In the previous week, BlackRock Capital Allocation Term Trust's average media sentiment score of 0.00 equaled abrdn Life Sciences Investors'average media sentiment score.

Company	Overall Sentiment
BlackRock Capital Allocation Term Trust	Neutral
abrdn Life Sciences Investors	Neutral

36.1% of BlackRock Capital Allocation Term Trust shares are owned by institutional investors. Comparatively, 32.2% of abrdn Life Sciences Investors shares are owned by institutional investors. 10.1% of abrdn Life Sciences Investors shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

BlackRock Capital Allocation Term Trust has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market. Comparatively, abrdn Life Sciences Investors has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
BlackRock Capital Allocation Term Trust	N/A	N/A	N/A
abrdn Life Sciences Investors	N/A	N/A	N/A

Summary

BlackRock Capital Allocation Term Trust beats abrdn Life Sciences Investors on 4 of the 5 factors compared between the two stocks.

Get abrdn Life Sciences Investors News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HQL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HQL vs. The Competition

Export

Metric	abrdn Life Sciences Investors	FIN Industry	Finance Sector	NYSE Exchange
Market Cap	$522.41M	$4.90B	$13.57B	$23.28B
Dividend Yield	11.87%	6.89%	5.76%	4.06%
P/E Ratio	N/A	0.02	19.70	31.00
Price / Sales	N/A	53.82	141.24	23.82
Price / Cash	N/A	5.15	19.87	24.93
Price / Book	N/A	3.24	2.17	4.67
Net Income	N/A	$388.27M	$1.13B	$1.07B
7 Day Performance	-4.30%	-0.51%	-0.74%	-1.10%
1 Month Performance	N/A	N/A	N/A	0.25%
1 Year Performance	34.71%	13.74%	11.15%	25.20%

abrdn Life Sciences Investors Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HQL abrdn Life Sciences Investors	N/A	$16.92 -1.5%	N/A	+34.9%	$522.41M	N/A	N/A	N/A
NUV Nuveen Municipal Value Fund	N/A	$9.09 +0.5%	N/A	+6.0%	$1.89B	$60.75M	N/A	640	Positive News Dividend Announcement
GAB Gabelli Equity Trust	N/A	$5.64 +0.3%	N/A	-3.3%	$1.75B	$305.25M	N/A	N/A	Positive News
USA Liberty All-Star Equity Fund	N/A	$5.82 -0.3%	N/A	-13.1%	$1.75B	N/A	N/A	N/A	Positive News
STEW SRH Total Return Fund	N/A	$17.63 -0.7%	N/A	-1.7%	$1.70B	$177.28M	N/A	N/A	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:HQL) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

abrdn Life Sciences Investors (HQL) Competitors

HQL vs. NUV, GAB, USA, STEW, and BCAT

How does abrdn Life Sciences Investors compare to Nuveen Municipal Value Fund?

Summary

How does abrdn Life Sciences Investors compare to Gabelli Equity Trust?

Summary

How does abrdn Life Sciences Investors compare to Liberty All-Star Equity Fund?

Summary

How does abrdn Life Sciences Investors compare to SRH Total Return Fund?

Summary

How does abrdn Life Sciences Investors compare to BlackRock Capital Allocation Term Trust?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HQL vs. The Competition

abrdn Life Sciences Investors Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

abrdn Life Sciences Investors (HQL) Competitors

HQL vs. NUV, GAB, USA, STEW, and BCAT

How does abrdn Life Sciences Investors compare to Nuveen Municipal Value Fund?

Do institutionals & insiders hold more shares of HQL or NUV?

Is HQL or NUV more profitable?

Is HQL or NUV a better dividend stock?

Which has better valuation & earnings, HQL or NUV?

Which has more volatility and risk, HQL or NUV?

Does the media prefer HQL or NUV?

Summary

How does abrdn Life Sciences Investors compare to Gabelli Equity Trust?

Is GAB or HQL more profitable?

Do institutionals and insiders hold more shares of GAB or HQL?

Which has stronger earnings & valuation, GAB or HQL?

Does the media refer more to GAB or HQL?

Which has more volatility & risk, GAB or HQL?

Is GAB or HQL a better dividend stock?

Summary

How does abrdn Life Sciences Investors compare to Liberty All-Star Equity Fund?

Does the media prefer USA or HQL?

Is USA or HQL more profitable?

Is USA or HQL a better dividend stock?

Which has more volatility and risk, USA or HQL?

Which has stronger earnings & valuation, USA or HQL?

Do insiders & institutionals believe in USA or HQL?

Summary

How does abrdn Life Sciences Investors compare to SRH Total Return Fund?

Do institutionals and insiders hold more shares of STEW or HQL?

Which has more risk & volatility, STEW or HQL?

Is STEW or HQL a better dividend stock?

Does the media refer more to STEW or HQL?

Which has better valuation and earnings, STEW or HQL?

Is STEW or HQL more profitable?

Summary

How does abrdn Life Sciences Investors compare to BlackRock Capital Allocation Term Trust?

Which has stronger valuation & earnings, BCAT or HQL?

Is BCAT or HQL a better dividend stock?

Does the media refer more to BCAT or HQL?

Do institutionals and insiders hold more shares of BCAT or HQL?

Which has more volatility & risk, BCAT or HQL?

Is BCAT or HQL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HQL vs. The Competition

abrdn Life Sciences Investors Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools